%0 Journal Article
%T Molecular Docking Studies on Streptomycin Antileishmanial Activity
%A Todd A. Young
%A Matthew George Jr.
%A Ayele Gugssa
%A William M. Southerland
%A Yayin Fang
%A Clarence M. Lee
%J Open Journal of Physical Chemistry
%P 36-48
%@ 2162-1977
%D 2024
%I Scientific Research Publishing
%R 10.4236/ojpc.2024.142003
%X Resistance to pentavalent antimonial drugs and the lack of vaccines make it urgent to find novel therapeutic options to treat Leishmaniasis, a tropical disease caused by the <i>Leishmania </i>protozoan parasite. The study reported here is to investigate if Streptomycin, an aminoglycoside, and Amphotericin B, the second-line treatment drug, exhibit antileishmanial activity through a similar mechanism. By using MOE (Molecular Operating Environment), we performed molecular docking studies on these drugs binding to a range of targets including ribosome targets in <i>Leishmania</i> and <i>H. sapiens.</i><i> </i>Our study shows that the two drugs do not bind to the same pockets in <i>Leishmania </i>targets but to the same pockets in the human ribosome, with some differences in interactions. Moreover, our 2D maps indicated that Amphotericin B binds to the A-site in the human cytoplasmic ribosome, whereas streptomycin does not.
%K Leishmaniasis
%K Streptomycin
%K Amphotericin B
%K Molecular Docking
%K Aminoglycosides
%K Antileishmanial
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=133079